Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,28 M
EBIT 2016 -53,2 M
Net income 2016 -51,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,47 M
EBIT 2017 -60,9 M
Net income 2017 -57,9 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 55,5x
Capi. / Sales2017 267x
Capitalization 127 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
06/29 ANTHERA PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and..
06/28 Anthera Provides Clinical Program Updates for Blisibimod and Sollpura®
06/22 ANTHERA PHARMACEUTICALS : Biotechnology Stocks in Motion -- Minerva Neuroscience..
06/15 ANTHERA PHARMACEUTICALS : Announces Presentation at JMP Securities Life Sciences..
05/31 ANTHERA PHARMACEUTICALS : Announces Presentation at Jefferies Healthcare Confere..
05/09 ANTHERA PHARMACEUTICALS : reports 1Q loss
05/09 Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quart..
04/30 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Change..
04/28 ANTHERA PHARMACEUTICALS : Greenphire Empowers Orphan Drug and Rare Disease Clini..
04/27 Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
More news
Sector news : Bio Therapeutic Drugs
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 10,6 $
Spread / Average Target 243%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paul F. Truex Chief Executive Officer & Director
John Craig Thompson President & Chief Operating Officer
Christopher S. Henney Chairman
May Liu CAO, Senior VP-Finance & Administration
Chuck Olson Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR127
AMGEN, INC.5.14%128 218
GILEAD SCIENCES, INC.-19.17%108 930
CELGENE CORPORATION-9.73%83 742
REGENERON PHARMACEUTIC..-23.54%43 617
VERTEX PHARMACEUTICALS..-23.70%23 748
More Results